Cargando…

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Danilov, Alexey V., Spurgeon, Stephen E., Siddiqi, Tanya, Quinson, Anne-Marie, Maier, Daniela, Smith, Dionne, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/
https://www.ncbi.nlm.nih.gov/pubmed/33683501
http://dx.doi.org/10.1007/s10637-020-01056-4
_version_ 1783722555550466048
author Danilov, Alexey V.
Spurgeon, Stephen E.
Siddiqi, Tanya
Quinson, Anne-Marie
Maier, Daniela
Smith, Dionne
Brown, Jennifer R.
author_facet Danilov, Alexey V.
Spurgeon, Stephen E.
Siddiqi, Tanya
Quinson, Anne-Marie
Maier, Daniela
Smith, Dionne
Brown, Jennifer R.
author_sort Danilov, Alexey V.
collection PubMed
description BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Eligible patients received 420 mg/day of ibrutinib with escalating doses of BI 836826. BI 836826 was administered in 4-week cycles. After Cycle 12, patients achieving complete response (CR), CR with incomplete marrow recovery, or minimal residual disease-negative partial response could continue to receive BI 836826 + ibrutinib every 4 weeks for ≤ 12 additional cycles. Patients received either 100 mg (n = 3) or 200 mg (n = 3) BI 836826 + ibrutinib. In the 100 mg BI 836826 cohort, one patient received two cycles and two patients received 22 cycles of BI 836826. In the 200 mg BI 836826 cohort, patients received 12, 16 and 20 cycles of BI 836826, respectively. All patients discontinued BI 836826 and continued ibrutinib outside the trial. No dose-limiting toxicities were reported in the maximum tolerated dose (MTD) evaluation period. As the trial was discontinued before the MTD was reached, the RP2D was not determined. Grade 3/4 adverse events (AEs) were predominantly hematological. Pseudomonal bacteremia was the only drug-related AE of special interest. BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial.
format Online
Article
Text
id pubmed-8279974
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82799742021-07-20 A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia Danilov, Alexey V. Spurgeon, Stephen E. Siddiqi, Tanya Quinson, Anne-Marie Maier, Daniela Smith, Dionne Brown, Jennifer R. Invest New Drugs Phase I Studies BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Eligible patients received 420 mg/day of ibrutinib with escalating doses of BI 836826. BI 836826 was administered in 4-week cycles. After Cycle 12, patients achieving complete response (CR), CR with incomplete marrow recovery, or minimal residual disease-negative partial response could continue to receive BI 836826 + ibrutinib every 4 weeks for ≤ 12 additional cycles. Patients received either 100 mg (n = 3) or 200 mg (n = 3) BI 836826 + ibrutinib. In the 100 mg BI 836826 cohort, one patient received two cycles and two patients received 22 cycles of BI 836826. In the 200 mg BI 836826 cohort, patients received 12, 16 and 20 cycles of BI 836826, respectively. All patients discontinued BI 836826 and continued ibrutinib outside the trial. No dose-limiting toxicities were reported in the maximum tolerated dose (MTD) evaluation period. As the trial was discontinued before the MTD was reached, the RP2D was not determined. Grade 3/4 adverse events (AEs) were predominantly hematological. Pseudomonal bacteremia was the only drug-related AE of special interest. BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial. Springer US 2021-03-08 2021 /pmc/articles/PMC8279974/ /pubmed/33683501 http://dx.doi.org/10.1007/s10637-020-01056-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Phase I Studies
Danilov, Alexey V.
Spurgeon, Stephen E.
Siddiqi, Tanya
Quinson, Anne-Marie
Maier, Daniela
Smith, Dionne
Brown, Jennifer R.
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title_full A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title_fullStr A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title_full_unstemmed A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title_short A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
title_sort phase ib, open label, dose escalation trial of the anti-cd37 monoclonal antibody, bi 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
topic Phase I Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/
https://www.ncbi.nlm.nih.gov/pubmed/33683501
http://dx.doi.org/10.1007/s10637-020-01056-4
work_keys_str_mv AT danilovalexeyv aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT spurgeonstephene aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT siddiqitanya aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT quinsonannemarie aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT maierdaniela aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT smithdionne aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT brownjenniferr aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT danilovalexeyv phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT spurgeonstephene phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT siddiqitanya phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT quinsonannemarie phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT maierdaniela phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT smithdionne phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia
AT brownjenniferr phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia